{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:25:54Z","timestamp":1785540354593,"version":"3.56.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Biallelic mutations in the <jats:italic>ACP5<\/jats:italic> gene cause spondyloenchondrodysplasia with immune dysregulation (SPENCDI). SPENCDI is characterized by the phenotypic triad of skeletal dysplasia, innate and adaptive immune dysfunction, and variable neurologic findings ranging from asymptomatic brain calcifications to severe developmental delay with spasticity. Immune dysregulation in SPENCDI is often refractory to standard immunosuppressive treatments. Here, we present the cases of two patients with SPENCDI and recalcitrant autoimmune cytopenias who demonstrated a favorable clinical response to targeted JAK inhibition over a period of more than 3 years. One of the patients exhibited steadily rising IgG levels and a bone marrow biopsy revealed smoldering multiple myeloma. A review of the literature uncovered that approximately half of the SPENCDI patients reported to date exhibited increased IgG levels. Screening for multiple myeloma in SPENCDI patients with rising IgG levels should therefore be considered.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1328005","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T04:35:25Z","timestamp":1706502925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report: Refractory Evans syndrome in two patients with spondyloenchondrodysplasia with immune dysregulation treated successfully with JAK1\/JAK2 inhibition"],"prefix":"10.3389","volume":"14","author":[{"given":"Yael","family":"Gernez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma-Martina","family":"Cepika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanita","family":"Valdes Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth G.","family":"Hoyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Mouradian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertil","family":"Glader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu","family":"Sathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latha","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Tolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Bacchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja G.","family":"Weinacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.748","article-title":"Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature","volume":"43","author":"Briggs","year":"2011","journal-title":"Nat Genet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0252-y","article-title":"Spondyloenchondrodysplasia due to mutations in ACP5: A comprehensive survey","volume":"36","author":"Briggs","year":"2016","journal-title":"J Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5546\/aap.2023-03031.eng","article-title":"Spondyloenchondrodysplasia with immune dysregulation related to ACP5. A report of 4 cases","volume":"122","author":"Dri","year":"2024","journal-title":"Arch Argent Pediatr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00438-023-02009-1","article-title":"Spondyloenchondrodysplasia in five new patients: identification of three novel ACP5 variants with variable neurological presentations","volume":"298","author":"Elhossini","year":"2023","journal-title":"Mol Genet Genomics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajmg.a.31526","article-title":"A syndrome of immunodeficiency, autoimmunity, and spondylometaphyseal dysplasia","author":"Kulkarni","year":"2007","journal-title":"Am J Med Genet A"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ng.749","article-title":"Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity","volume":"43","author":"Lausch","year":"2011","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.32518","article-title":"Two further cases of spondyloenchondrodysplasia (SPENCD) with immune dysregulation","author":"Navarro","year":"2008","journal-title":"Am J Med Genet A"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.31081","article-title":"Spondyloenchondrodysplasia with spasticity, cerebral calcifications, and immune dysregulation: clinical and radiographic delineation of a pleiotropic disorder","volume":"140","author":"Renella","year":"2006","journal-title":"Am J Med Genet A"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0004.2003.00033.x","article-title":"A novel syndrome of combined immunodeficiency, autoimmunity and spondylometaphyseal dysplasia","volume":"63","author":"Roifman","year":"2003","journal-title":"Clin Genet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/art.39810","article-title":"Tartrate-resistant acid phosphatase deficiency in the predisposition to systemic lupus erythematosus","volume":"69","author":"An","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"104286","DOI":"10.1016\/j.ejmg.2021.104286","article-title":"Spondylenchondrodysplasia mimicking a systemic lupus erythematosus: A diagnostic challenge in a pediatric patient","volume":"64","author":"Baglan","year":"2021","journal-title":"Eur J Med Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-020-03636-x","article-title":"Monogenic lupus with igA nephropathy caused by spondyloenchondrodysplasia with immune dysregulation","volume":"88","author":"Sait","year":"2021","journal-title":"Indian J Pediatr"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26195","article-title":"Childhood-onset autoimmune cytopenia as the presenting feature of biallelic ACP5 mutations","volume":"64","author":"Sacri","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2014.10.005","article-title":"Type I interferonopathies: mendelian type I interferon up-regulation","volume":"32","author":"Crow","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0359-1","article-title":"Assessment of type I interferon signaling in pediatric inflammatory disease","volume":"37","author":"Rice","year":"2017","journal-title":"J Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children","volume":"138","author":"Fremond","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","article-title":"Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation","volume":"139","author":"Weinacht","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01400-8","article-title":"SPENCD presenting with evans phenotype and clinical response to JAK1\/2 inhibitors-a report of 2 cases","volume":"43","author":"Chougule","year":"2023","journal-title":"J Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.825367","article-title":"Janus kinase inhibitors in the treatment of type I interferonopathies: A case series from a single center in China","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6491","DOI":"10.3390\/jcm11216491","article-title":"Pathways of angiogenic and inflammatory cytokines in multiple myeloma: role in plasma cell clonal expansion and drug resistance","volume":"11","author":"Melaccio","year":"2022","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0287-0","article-title":"Erratum to: spondyloenchondrodysplasia due to mutations in ACP5: A comprehensive survey","volume":"36","author":"Briggs","year":"2016","journal-title":"J Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jaip.2020.11.007","article-title":"Overview of STING-associated vasculopathy with onset in infancy (SAVI) among 21 patients","volume":"9","author":"Fremond","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04653-x","article-title":"Monogenic lupus due to spondyloenchondrodysplasia with spastic paraparesis and intracranial calcification: case-based review","volume":"40","author":"Kara","year":"2020","journal-title":"Rheumatol Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.12.009","article-title":"Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations","volume":"188","author":"Besnard","year":"2018","journal-title":"Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13600","article-title":"Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation","volume":"106","author":"Grimes","year":"2021","journal-title":"Eur J Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2018-11-887141","article-title":"Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes","volume":"134","author":"Hadjadj","year":"2019","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869033","article-title":"Underlying inborn errors of immunity in patients with evans syndrome and multilineage cytopenias: A single-centre analysis","volume":"13","author":"Miano","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01510","article-title":"Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system","volume":"9","author":"Kubo","year":"2018","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2016.10.005","article-title":"Impact of tofacitinib treatment on human B-cells in vitro and in vivo","volume":"77","author":"Rizzi","year":"2017","journal-title":"J Autoimmun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00506","article-title":"Patterns of ruxolitinib therapy failure and its management in myelofibrosis: perspectives of the canadian myeloproliferative neoplasm group","volume":"16","author":"Gupta","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in UBA1 as a cause of VEXAS syndrome","volume":"137","author":"Poulter","year":"2021","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"Georgin-Lavialle","year":"2022","journal-title":"Br J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654406","article-title":"Clinical relevance of gain- and loss-of-function germline mutations in STAT1: A systematic review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18593","article-title":"Ruxolitinib and methylprednisolone for treatment of patients with relapsed\/refractory multiple myeloma","volume":"200","author":"Berenson","year":"2023","journal-title":"Br J Haematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2001362","article-title":"Janus kinase inhibition in the aicardi-goutieres syndrome","volume":"383","author":"Vanderver","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1328005\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T04:35:28Z","timestamp":1706502928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1328005\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2023.1328005"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1328005","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"article-number":"1328005"}}